Abivax posts Phase 3 results for obefazimod in ulcerative colitis across ABTECT-1 and ABTECT-2

Abivax S.A. posted results this week for two Phase 3 induction studies of obefazimod (ABX464) in ulcerative colitis, both completed after enrolling patients who had not responded well to prior treatments.

• "ABTECT-1" (NCT05507203, sponsor ID ABX464-105) is a completed Phase 3 trial testing ABX464 at 25 or 50 mg given once daily to induce clinical remission in patients with moderately to severely active ulcerative colitis.¹ The study enrolled 639 participants¹ and had its primary outcome set as the proportion of subjects achieving clinical remission per Modified Mayo Score at Week 8, comparing ABX464 to placebo.¹ Results were first posted September 10, 2026.
• "ABTECT-2" (NCT05507216, sponsor ID ABX464-106) is a completed Phase 3 trial with the same dosing design, testing ABX464 at 25 or 50 mg once daily to induce clinical remission in patients with moderately to severely active ulcerative colitis.² This study enrolled 636 participants² and shared the same primary endpoint of clinical remission per Modified Mayo Score at Week 8 versus placebo.² Results were also first posted September 10, 2026.